Compare VOYA & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VOYA | IMVT |
|---|---|---|
| Founded | 1975 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 8.5B |
| IPO Year | 2012 | 2019 |
| Metric | VOYA | IMVT |
|---|---|---|
| Price | $95.88 | $28.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 17 |
| Target Price | ★ $107.83 | $48.88 |
| AVG Volume (30 Days) | 840.6K | ★ 1.4M |
| Earning Date | 11-02-2026 | 11-09-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | ★ 1.94 | N/A |
| EPS | ★ 2.73 | N/A |
| Revenue | ★ $8,189,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $36.04 | ★ N/A |
| Revenue Growth | ★ 1.73 | N/A |
| 52 Week Low | $64.50 | $19.21 |
| 52 Week High | $105.64 | $45.42 |
| Indicator | VOYA | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 32.15 |
| Support Level | $92.30 | $25.83 |
| Resistance Level | $104.18 | $29.83 |
| Average True Range (ATR) | 2.04 | 1.24 |
| MACD | 0.30 | 0.16 |
| Stochastic Oscillator | 44.29 | 31.44 |
Voya Financial Inc is a financial services company, which, through its subsidiaries, provides various investment, insurance, and retirement solutions to individual and institutional clients in the United States. Its products and services include tax savings plans, individual retirement accounts, group life insurance plans, and employee benefits products, among others. The company tailors each of its products to the needs of its customer base. It operates its business through three principal lines: Retirement, Investment Management and Employee Benefits.The majority revenue is from Retirement segment.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.